Ert Pompe denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies ERT for Pompe Disease as Experimental

An experimental or investigational denial is among the most serious — and most commonly overturned — denials for rare-disease therapies. UnitedHealthcare may apply this label using a coverage determination policy that has not been updated to reflect current FDA approval status, or it may be triggered by a billing code associated with an investigational context (such as an infusion administered at a research site).

For Pompe disease, enzyme replacement therapy has FDA approval. That approval is the cornerstone of your appeal.

## Why This Denial Is Appealable

Federal and state law prohibit insurers from categorically denying FDA-approved treatments as experimental solely on the basis of internal policy definitions that conflict with the FDA's determination. The applicable standard of care is defined by the FDA-approved prescribing information and by the relevant professional society guidelines (such as those from the American College of Medical Genetics and Genomics or the relevant neuromuscular specialty societies). An insurer's internal "experimental" label does not override a valid FDA approval.

## Federal Appeal Framework

• ERISA §503 requires a full-and-fair review; the plan must provide the specific clinical rationale and the medical literature it relied upon to call the treatment experimental.
• ACA §2719 mandates external review for experimental/investigational denials specifically — this is one of the strongest external-review triggers. An accredited IRO will apply an evidence-based standard, not the plan's internal policy.
• The external-review request window is typically within approximately four months of denial. Check your Explanation of Benefits for the exact deadline.
• Expedited review: Given that Pompe disease is a progressive condition where delays cause irreversible muscle and respiratory decline, expedited review is appropriate and should be requested.

## Concrete Appeal Steps

1. Obtain a copy of UHC's experimental/investigational coverage policy for this specific drug or drug class. 2. Obtain the current FDA product label confirming approval status and approved indication. 3. File an internal appeal with the documentation below; simultaneously request expedited review if your condition is urgent. 4. If denied internally, file for external review immediately.

## Documentation to Gather

• FDA approval evidence: The current FDA-approved prescribing label for the specific ERT prescribed, confirming the indication covers your diagnosis.
• Diagnosis confirmation: Genetic confirmation of pathogenic GAA variants; enzyme activity assay; clinical documentation of disease phenotype (infantile-onset or late-onset).
• Clinical severity and progression: Pulmonary function trend (FVC on serial testing), motor assessments, and any acute events documented in the chart.
• Professional society guideline reference: A letter from your specialist citing the relevant guideline organization's recommendation for ERT in confirmed Pompe disease — without quoting specific numbers, noting that the guidelines endorse treatment for your confirmed disease stage.
• Prescriber medical-necessity letter: Explicit statement that this is an FDA-approved therapy used on-label for a confirmed genetic diagnosis.

## Criteria-Mapping Structure

Request the exact language from UHC's policy defining "experimental." Map each element:

| Policy Criterion | Your Evidence | |---|---| | FDA approval status | Current FDA label — approved indication matches diagnosis | | Professional society endorsement | Specialist letter citing guideline organization | | Scientific evidence of efficacy | Specialist's clinical assessment of established standard of care |

Submit this mapping as a cover page to your appeal packet.